Poster: ABCL-040: Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent Bruton’s Tyrosine Kinase Inhibitor in Previously Treated Mantle Cell Lymphoma and Other Non-Hodgkin Lymphomas: Phase 1/2 BRUIN Study Results
Keyword(s):
Phase 1
◽
2020 ◽
Vol 34
(5)
◽
pp. 923-939
2020 ◽
Vol 20
◽
pp. S259-S260
2018 ◽
pp. molcanther.0478.2018
◽
2021 ◽
Vol 27
(3)
◽
pp. S341-S342